128 related articles for article (PubMed ID: 25627776)
1. Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Mita S; Meyers D; Pal P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
Clin Pharmacokinet; 2015 Jul; 54(7):751-60. PubMed ID: 25627776
[TBL] [Abstract][Full Text] [Related]
2. Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
Hirano M; Meyers D; Golla G; Pal P; Pinot P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
Clin Pharmacokinet; 2015 Jul; 54(7):761-70. PubMed ID: 25633714
[TBL] [Abstract][Full Text] [Related]
3. Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
Chen J; Bhansali S; Neelakantham S; Trusley C; Majumdar T; Rebello S; Sunkara G; Meyers C
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):317-24. PubMed ID: 25740268
[TBL] [Abstract][Full Text] [Related]
4. Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
Meyers CD; Noe A; Salunke A; Movva A; Kulmatycki K; Neelakantham S; Crissey A; Majumdar T; Chen J
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):450-459. PubMed ID: 27274009
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
Yan JH; Meyers D; Lee Z; Danis K; Neelakantham S; Majumdar T; Rebello S; Sunkara G; Chen J
J Clin Pharmacol; 2014 Jul; 54(7):800-8. PubMed ID: 24619917
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
Meyers CD; Amer A; Majumdar T; Chen J
J Clin Pharmacol; 2015 Sep; 55(9):1031-41. PubMed ID: 25854859
[TBL] [Abstract][Full Text] [Related]
7. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
Meyers CD; Tremblay K; Amer A; Chen J; Jiang L; Gaudet D
Lipids Health Dis; 2015 Feb; 14():8. PubMed ID: 25889044
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor.
Ayalasomayajula SP; Meyers CD; Yu J; Kagan M; Matott R; Pal P; Majumdar T; Su Z; Crissey A; Rebello S; Sunkara G; Chen J
Biopharm Drug Dispos; 2015 Oct; 36(7):452-61. PubMed ID: 25963481
[TBL] [Abstract][Full Text] [Related]
9. Pradigastat disposition in humans: in vivo and in vitro investigations.
Upthagrove A; Chen J; Meyers CD; Kulmatycki K; Bretz A; Wang L; Peng L; Palamar S; Lin M; Majumdar T; Tran P; Einolf HJ
Xenobiotica; 2017 Dec; 47(12):1077-1089. PubMed ID: 27855567
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
11. The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions.
Bauer D; Soon RL; Kulmatycki K; Chen Y; Noe A; Chen J; Dosik JS; Meyers D
Photochem Photobiol Sci; 2016 Aug; 15(9):1155-1162. PubMed ID: 27471837
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects.
Ayalasomayajula S; Meyers D; Koo P; Salunke A; Majumdar T; Rebello S; Sunkara G; Chen J
Eur J Clin Pharmacol; 2015 Apr; 71(4):425-32. PubMed ID: 25724644
[TBL] [Abstract][Full Text] [Related]
13. A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial.
Gane E; Stedman C; Dole K; Chen J; Meyers CD; Wiedmann B; Zhang J; Raman P; Colvin RA
ACS Infect Dis; 2017 Feb; 3(2):144-151. PubMed ID: 27788579
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
[TBL] [Abstract][Full Text] [Related]
15. Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Mendonza A; Hanna I; Meyers D; Koo P; Neelakantham S; Zhu B; Majumdar T; Rebello S; Sunkara G; Chen J
J Clin Pharmacol; 2016 Mar; 56(3):355-64. PubMed ID: 26189431
[TBL] [Abstract][Full Text] [Related]
16. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
[TBL] [Abstract][Full Text] [Related]
17. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
18. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
[TBL] [Abstract][Full Text] [Related]
19. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
20. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
